Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High HLA group CBU infusion
- Development stage
- Unknown
- Lead developer
- Samara Regional Medical Center Dinasty
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
High HLA group CBU infusion is an allogeneic cell therapy consisting of umbilical cord blood mononuclear cells (CB-MNCs) characterized by a high degree of Human Leukocyte Antigen (HLA) compatibility. In the context of clinical protocols developed by the Samara Regional Medical Center Dinasty, "High HLA" is defined as a compatibility of 4 or more matches at the A, B, and DRB1 loci between the donor and the recipient. This therapy is being investigated for the treatment of infantile cerebral palsy, a condition resulting from non-progressive brain lesions. The treatment involves the intravenous administration of hematopoietic and other progenitor cells found in cord blood, which are thought to promote neurological repair, provide neuroprotection, and modulate inflammatory responses. The specific use of high HLA-matched units is intended to evaluate whether increased tissue compatibility improves the safety profile and clinical efficacy of the transfusion compared to lower-matched samples.
- Other names
- High HLA group umbilical cord blood mononuclear cellsHigh HLA group CB-MNCHigh HLA group CBU
Beyond the preview
Go deeper on High HLA group CBU infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on High HLA group CBU infusion.